Dilafor AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Dilafor AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0478
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dilafor AB (Dilafor) is a drug development company that develops pharmaceutical products for obstetric indications. The company offers tafoxiparin, a proprietary heparan sulfate mimetic, which is used as an adjuvant therapy to promote cervical ripening and myometrial contractility. Its tafoxiparin helps to improve uterine contractions and promote cervical softening and potential to reduce the incidence of protracted labor and associated complications. Dilafor carries out clinical trials to evaluate the safety and pharmacokinetics of tafoxiparinfor and other various indications within the obstetric field in Sweden and Finland. The company works in partnership with other pharmaceutical companies. Dilafor is headquartered in Solna, Sweden.

Dilafor AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dilafor AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Dilafor AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Dilafor AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Dilafor Raises USD6 Million in Venture Financing 10
Licensing Agreements 11
Dilafor Enters Into Licensing Agreement With Lee’s Pharma 11
Acquisition 12
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 12
Dilafor AB – Key Competitors 15
Dilafor AB – Key Employees 16
Dilafor AB – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Dilafor AB, Pharmaceuticals & Healthcare, Key Facts 2
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dilafor AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dilafor AB, Deals By Therapy Area, 2012 to YTD 2018 8
Dilafor AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Dilafor Raises USD6 Million in Venture Financing 10
Dilafor Enters Into Licensing Agreement With Lee’s Pharma 11
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 12
Dilafor AB, Key Competitors 15
Dilafor AB, Key Employees 16

List of Figures
Dilafor AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dilafor AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dilafor AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Dilafor AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • National Taiwan University Hospital-製薬・医療分野:企業M&A・提携分析
    Summary National Taiwan University Hospital (NTUH) is a healthcare service provider that offers biomedical, clinical research and patient care services. The hospital’s research activities include community-based intervention programs, multicenter controlled clinical trials, program projects, researc …
  • Aurobindo Pharma Ltd (AUROPHARMA)-製薬・医療分野:企業M&A・提携分析
    Summary Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceutical company which develops, manufactures and exports formulations and active pharmaceutical ingredients (API's). Its products portfolio include active pharma ingredients, formulations, antibiotics, anti-retrovirals, anti- allergics, gas …
  • Clalit Health Services:企業の戦略的SWOT分析
    Clalit Health Services - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Bemis Company Inc (BMS):企業の財務・戦略的SWOT分析
    Bemis Company Inc (BMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Kathmandu Holdings Limited:企業の戦略・SWOT・財務情報
    Kathmandu Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Kathmandu Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Bechtel Corporation:電力:M&Aディール及び事業提携情報
    Summary Bechtel Corporation (Bechtel) is a provider of engineering, construction and project management services. It provides a diverse portfolio of services to energy, transportation, infrastructure, communications, mining and metals, oil and gas, chemicals, water, defense and nuclear, and governme …
  • Transcontinental Inc (TCL.A):企業の財務・戦略的SWOT分析
    Transcontinental Inc (TCL.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • CBT Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CBT Pharmaceuticals Inc (CBT) is a pharmaceutical company that develops innovative medicines for cancer indications. The company's pipeline products include CBT-101, cMet inhibitor is being developed to target the epithelial to mesenchymal transition pathway. Its CBT-101 is developed for var …
  • UK Green Investment Bank Ltd:電力:M&Aディール及び事業提携情報
    Summary UK Green Investment Bank Ltd (UK Green) is an investment firm that offers green infrastructure investment services in the UK. The firm primarily invests on renewable energy and energy efficiency projects that include offshore wind, green deals and waste and bio energy and onshore renewable e …
  • Yingli Green Energy Holding Company Limited (YGE):電力:M&Aディール及び事業提携情報
    Summary Yingli Green Energy Holding Company Limited (Yingli Solar) is a solar panel manufacturer. It designs, assembles, sells, and installs solar PV systems. It covers the entire value chain of solar PV industry ranging from designing to manufacturing of multicrystalline polysilicon ingots, wafers, …
  • Alfa SAB de CV (ALFAA):企業の財務・戦略的SWOT分析
    Alfa SAB de CV (ALFAA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Abreos Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Abreos Biosciences Inc (Abreos Biosciences) is a biotechnology company that develops laboratory-based and point-of-care (POC) tests for precision dosing of biologic drugs. The company’s technology platform veritope, allow monitoring of monoclonal antibody drug levels in blood (novel or biosi …
  • ContourGlobal LP-エネルギー分野:企業M&A・提携分析
    Summary ContourGlobal L.P. (CGLP) is an energy company that owns and operates of power generation assets. It develops, acquires and operates electric power and district heating businesses. The company develops and operates large central power plants in emerging markets to support the growth of the n …
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349):企業の財務・戦略的SWOT分析
    Summary Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (FDZJ), a subsidiary of Shanghai Pharmaceutical Co Ltd, is a bio-pharmaceutical company that develops, manufactures and markets genetic engineering drugs. The company offers bio-pharmaceutical products in the field of genetic engineering, p …
  • Elia System Operator SA (ELI):電力:M&Aディール及び事業提携情報
    Summary Elia System Operator SA (Elia) is a transmission system operator. It owns and operates high-voltage electricity transmission systems in Belgium and Germany. The company transmits electricity from generators to distribution system operators and industrial consumers. Elia also imports and expo …
  • Boursorama SA:企業の戦略・SWOT・財務情報
    Boursorama SA - Strategy, SWOT and Corporate Finance Report Summary Boursorama SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Seattle Genetics Inc (SGEN):企業の財務・戦略的SWOT分析
    Seattle Genetics Inc (SGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Laboratorios SALVAT SA-製薬・医療分野:企業M&A・提携分析
    Summary Laboratorios SALVAT SA (SALVAT) is a manufacturer of pharmaceutical products for healthcare industries. The company offers prescription and over-the- counter drugs in various segments such as personal healthcare, metabolism, urology, ophtholmology, dermatology and malaria. Its personal healt …
  • Crisil Ltd (CRISIL):企業の財務・戦略的SWOT分析
    Summary Crisil Ltd (Crisil), a subsidiary of S&P Global Inc is a financial service provider that offers risk management services. The company provides ratings, research and risk and policy advisory services. It offers services such as credit ratings, business school gradings, real estate star rating …
  • Sandvine Corporation:企業の戦略的SWOT分析
    Sandvine Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆